These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34140105)

  • 21. Prevalent use of high-intensity statin therapy and LDL-C target attainment among PAD patients undergoing angioplasty.
    Wolf S; Spirk D; Forgo G; Sebastian T; Voci D; Kucher N; Barco S
    Vasa; 2022 Nov; 51(6):357-364. PubMed ID: 36052607
    [No Abstract]   [Full Text] [Related]  

  • 22. Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol? : a retrospective study.
    Wongcharoen W; Sutthiwutthichai S; Gunaparn S; Phrommintikul A
    BMC Cardiovasc Disord; 2017 Jan; 17(1):10. PubMed ID: 28056802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
    Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
    Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
    Colhoun HM; Leiter LA; Müller-Wieland D; Cariou B; Ray KK; Tinahones FJ; Domenger C; Letierce A; Israel M; Samuel R; Del Prato S
    Cardiovasc Diabetol; 2020 Feb; 19(1):14. PubMed ID: 32035487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease.
    Nastasi DR; Moxon JV; Norman R; Trollope AF; Rowbotham S; Quigley F; Jenkins J; Golledge J
    J Vasc Surg; 2021 Apr; 73(4):1396-1403.e3. PubMed ID: 32891803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
    Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
    Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
    De Ferrari GM; Perna GP; Nicosia A; Guasti L; Casu G; Cuccia C; Picco F; Strazzella C; Totaro R; Cercone S; Canullo L; Horack M; Lautsch D; Gitt AK; Di Biase M
    J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):485-490. PubMed ID: 29917002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.
    Ray KK; Ginsberg HN; Davidson MH; Pordy R; Bessac L; Minini P; Eckel RH; Cannon CP
    Circulation; 2016 Dec; 134(24):1931-1943. PubMed ID: 27777279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Low-Density Lipoprotein Cholesterol Level After Endovascular Therapy in Patients With Claudication.
    Tomoi Y; Yamaji K; Soga Y; Hiramori S; Ando K
    J Endovasc Ther; 2019 Jun; 26(3):402-410. PubMed ID: 30873910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study.
    Li Z; Gao Y; Lu Q; Yin Z; Zhang S; Zhang W; Sui Y; Xu Y; Li J; Dou K; Qian J; Qiu H; Wu N
    Lipids Health Dis; 2024 May; 23(1):134. PubMed ID: 38715079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of Lipid-Lowering Therapy for High Cardiovascular Risk Patients Through Electronic Medical Record Reporting and Pharmacist Evaluation.
    Chen K; Canfield S; Blackwell J; Houmes S; Jones S; Lindsley J
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1010-1016. PubMed ID: 32715962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J.
    Nakamura M; Ako J; Arai H; Hirayama A; Nohara A; Murakami Y; Ozaki A; Harada-Shiba M
    J Atheroscler Thromb; 2021 Dec; 28(12):1307-1322. PubMed ID: 33612707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications of the 2013 ACC/AHA cholesterol guidelines on contemporary clinical practice for patients with atherosclerotic coronary and peripheral arterial disease.
    Gunasekaran P; Jeevanantham V; Sharma S; Thapa R; Gupta K
    Indian Heart J; 2017; 69(4):464-468. PubMed ID: 28822512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease.
    West AM; Anderson JD; Epstein FH; Meyer CH; Wang H; Hagspiel KD; Berr SS; Harthun NL; Weltman AL; Dimaria JM; Hunter JR; Christopher JM; Kramer CM
    J Am Coll Cardiol; 2011 Aug; 58(10):1068-76. PubMed ID: 21867844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol.
    Ogita M; Miyauchi K; Miyazaki T; Naito R; Konishi H; Tsuboi S; Dohi T; Kasai T; Yokoyama T; Okazaki S; Kurata T; Daida H
    Heart Vessels; 2014 Jan; 29(1):35-41. PubMed ID: 23516028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impact.
    Bauters C; Tricot O; Lemesle G; Meurice T; Hennebert O; Farnier M; Lamblin N
    Arch Cardiovasc Dis; 2018 Nov; 111(11):634-643. PubMed ID: 29198936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.